thalidomide has been researched along with Benign Monoclonal Gammopathies in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up-front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS, n = 21), smouldering MM (SMM, n = 22) or solitary plasmacytoma of bone (SPC, n = 13)." | 5.12 | Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. ( Anaissie, E; Arzoumanian, V; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Krishna, S; Pineda-Roman, M; Shaughnessy, JD; van Rhee, F; Walker, R; Zangari, M, 2007) |
| " The patient re-achieved molecular remission after resumption of imatinib, but his MGUS progressed to smoldering myeloma and he was eventually diagnosed with multiple myeloma (MM) and initiated on treatment for MM with thalidomide, bortezomib and dexamethasone." | 3.96 | Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient. ( Dourado, C; Gupta, S; Swaminathan, N, 2020) |
| "Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance is a rare subacute adult-onset myopathy." | 1.48 | Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS): An alternative treatment using cyclophosphamide-thalidomide-dexamethasone (CTD) regimen. ( Boonyapisit, K; Kumutpongpanich, T; Nishino, I; Owattanapanich, W; Tanboon, J, 2018) |
| "The abnormal cell types in chronic myeloid leukemia (CML) and monoclonal gammopathy of uncertain (MGUS) are quite different, being myeloid and plasma cells, respectively." | 1.48 | Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report. ( Lu, S; Ouyang, W; Wang, Z; Zhao, X, 2018) |
| "Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is usually only treated by a form of anti-multiple myeloma therapy if it is causing substantial disease through deposition of secreted M proteins." | 1.46 | Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. ( Afzal, Z; Bunce, CM; Cairns, DA; Campbell, JP; Child, JA; Drayson, MT; Gregory, W; Heaney, JLJ; Jackson, GH; Kaiser, M; Morgan, GJ; Owen, R; Pandya, S, 2017) |
| "Secondary monoclonal gammopathy of undetermined significance (MGUS) is a special phenomenon that occurs during the treatment of multiple myeloma (MM)." | 1.40 | Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. ( An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Swaminathan, N | 2 |
| Gupta, S | 2 |
| Dourado, C | 2 |
| Abe, N | 1 |
| Tomita, T | 1 |
| Bohgaki, M | 1 |
| Kasahara, H | 1 |
| Koike, T | 1 |
| Campbell, JP | 1 |
| Heaney, JLJ | 1 |
| Pandya, S | 1 |
| Afzal, Z | 1 |
| Kaiser, M | 1 |
| Owen, R | 1 |
| Child, JA | 1 |
| Cairns, DA | 1 |
| Gregory, W | 1 |
| Morgan, GJ | 2 |
| Jackson, GH | 1 |
| Bunce, CM | 1 |
| Drayson, MT | 1 |
| Kumutpongpanich, T | 1 |
| Owattanapanich, W | 1 |
| Tanboon, J | 1 |
| Nishino, I | 1 |
| Boonyapisit, K | 1 |
| Ouyang, W | 1 |
| Zhao, X | 1 |
| Lu, S | 1 |
| Wang, Z | 1 |
| Tovar, N | 1 |
| Fernández de Larrea, C | 1 |
| Pedrosa, F | 1 |
| Aróstegui, JI | 1 |
| Cibeira, MT | 1 |
| Rosiñol, L | 1 |
| Elena, M | 1 |
| Filella, X | 1 |
| Yagüe, J | 1 |
| Bladé, J | 1 |
| Zou, D | 1 |
| An, G | 1 |
| Zhu, G | 1 |
| Wang, J | 1 |
| Shi, L | 1 |
| Meng, H | 1 |
| Xu, Y | 1 |
| Sui, W | 1 |
| Deng, S | 1 |
| Zhan, F | 1 |
| Qiu, L | 1 |
| Kawano, Y | 1 |
| Moschetta, M | 1 |
| Manier, S | 1 |
| Glavey, S | 1 |
| Görgün, GT | 1 |
| Roccaro, AM | 1 |
| Anderson, KC | 1 |
| Ghobrial, IM | 1 |
| Ouyang, HY | 1 |
| Yu, ZJ | 1 |
| Yin, J | 1 |
| Zhao, XJ | 1 |
| Wang, ZY | 1 |
| Zhang, W | 1 |
| Ma, ZN | 1 |
| Su, J | 1 |
| Bai, X | 1 |
| Ruan, CG | 1 |
| Silapunt, S | 1 |
| Chon, SY | 1 |
| Walker, BA | 1 |
| Wardell, CP | 1 |
| Chiecchio, L | 1 |
| Smith, EM | 1 |
| Boyd, KD | 1 |
| Neri, A | 1 |
| Davies, FE | 1 |
| Ross, FM | 1 |
| Dezube, BJ | 1 |
| Aboulafia, DM | 1 |
| Pantanowitz, L | 1 |
| Pineda-Roman, M | 1 |
| Bolejack, V | 1 |
| Arzoumanian, V | 1 |
| Anaissie, E | 1 |
| van Rhee, F | 1 |
| Zangari, M | 1 |
| Walker, R | 1 |
| Hollmig, K | 1 |
| Shaughnessy, JD | 1 |
| Epstein, J | 1 |
| Krishna, S | 1 |
| Crowley, J | 1 |
| Barlogie, B | 1 |
| Kyrtsonis, MC | 1 |
| Kokoris, SI | 1 |
| Kontopidou, FN | 1 |
| Siakantaris, MP | 1 |
| Kittas, C | 1 |
| Pangalis, GA | 1 |
3 reviews available for thalidomide and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Tr | 2015 |
[Acquired von Willebrand syndrome in three patients and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hemorrhage; Humans; Immunoglobulins, I | 2016 |
Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; HIV Infect | 2004 |
2 trials available for thalidomide and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cluster Analysis; Cyclophosphamide; Dexamethasone; D | 2011 |
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 2007 |
9 other studies available for thalidomide and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chron | 2020 |
Crystalglobulinemia manifesting as chronic arthralgia and acute limb ischemia: A clinical case report.
Topics: Amputation, Surgical; Arterial Occlusive Diseases; Arthralgia; Bortezomib; Dexamethasone; Humans; Le | 2017 |
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Mon | 2017 |
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS): An alternative treatment using cyclophosphamide-thalidomide-dexamethasone (CTD) regimen.
Topics: Adult; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Humans; Immunosuppressive Agents; | 2018 |
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report.
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mo | 2018 |
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Prog | 2014 |
Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Dexamethasone; Granuloma; Humans; Lenalidomide; Male; Monoclonal Gammopathy | 2010 |
Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Disease Progression; Humans; Im | 2001 |